

REGENERON PHARMACEUTICALS INC

Form 8-K

April 16, 2003

Table of Contents

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D. C. 20549**

---

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

---

Date of Report: April 14, 2003  
(Date of earliest event reported)

**REGENERON PHARMACEUTICALS, INC.**

(Exact name of Registrant as specified in its charter)

New York  
(State or Other Jurisdiction of  
Incorporation)

0-19034  
(Commission File Number)

13-3444607  
(IRS Employer  
Identification No.)

**777 Old Saw Mill River Road  
Tarrytown, NY 10591-6707**  
(Address of principal executive offices, including zip code)

Registrant's telephone number, including area code: (914) 347-7000

---

**TABLE OF CONTENTS**

ITEM 5. OTHER EVENTS

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND  
EXHIBITS

SIGNATURES

PRESS RELEASE

---

**Table of Contents**

**ITEM 5. OTHER EVENTS**

On April 14, 2003, the Company issued a press release announcing the results of its Phase II trial evaluating AXOKINE® for weight loss in overweight and obese people with type 2 diabetes.

**ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS**

(c) Exhibits.

99a Press Release dated April 14, 2003

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

REGENERON PHARMACEUTICALS, INC.

By: /s/ Stuart Kolinski

---

Name: Stuart Kolinski  
Title: Vice President & General Counsel

Date: April 16, 2003